Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for ABS-201 in Androgenetic alopecia. The expected timing is based on the latest available company guidance and may change.
10/15/25- Initiate Ph1/2a trial in early December. 03/24/26:- HEADLINE Ph1/2a dosed first three SAD cohorts; preliminary safety and pharmacokinetic data H1 2026; proof-of-concept data H2 2026–early 2027. 05/07/26:- Completed 4 SAD cohorts; MAD dosing started. Safety/tolerability/PK data Q2 2026; interim POC H2 2026; full POC 2027. 06/24/26:- Interim Phase 1 data positive; MAD started. Interim POC data expected H2 2026; full POC data Early 2027. 08/11/26:- Positive interim Phase 1 HEADLINE data reported. Interim proof-of-concept data is expected in H2 2026; full data is expected in Early 2027.
Verification
Confirm timing and program details against the company announcement or filing.